Cytomegalovirus Infection and Disease Following Renal Transplantation: Preliminary Report of Incidence and Potential Risk Factors

Transplantation Proceedings

Volumn 41, Issue 7, 2009, Pages 2841-2844

  Taherimahmoudi, M ^a   Ahmadi, H ^a   Baradaran, N ^a   Montaser Kouhsari, L ^a   Salem, S ^a   Mehrsai, A ^a   Kalantar, E ^b   Jahani, Y ^c   Pourmand, G ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GANCICLOVIR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THYMOCYTE ANTIBODY; VIRUS DNA;

ADULT; ARTICLE; BLOOD CELL COUNT; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG DOSE REDUCTION; FEMALE; GRAFT RECIPIENT; HUMAN; INCIDENCE; INFECTION RISK; KIDNEY FUNCTION TEST; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LABORATORY TEST; LIVER FUNCTION TEST; MALE; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; ANTIGENS, VIRAL; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; REGRESSION ANALYSIS; RENAL REPLACEMENT THERAPY; REOPERATION; RISK FACTORS;

EID: 70149101109     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.07.027     Document Type: Article

References (22)

1. Sagedal S., Hartmann A., Nordal K.P., et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 66 (2004) 329
2. Brennan D.C. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 12 (2001) 848
3. Rizvi S.A., Naqvi S.A., Hussain Z., et al. Renal transplantation in developing countries. Kidney Int Suppl 83 (2003) S96
4. Nemati E., Eizadi M., Lankarani M.M., et al. Cytomegalovirus disease after kidney transplantation: clues to accurate diagnosis. Transplant Proc 39 (2007) 987
5. Ljungman P., Griffiths P., and Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34 (2002) 1094
6. Pourmand G., Salem S., Mehrsai A., et al. Infectious complications after kidney transplantation: a single-center experience. Transpl Infect Dis 9 (2007) 302
7. Razeghi E., Hadadi A., Mansor-Kiaei M., et al. Clinical manifestation, laboratory findings, and the response of treatment in kidney transplant recipients with CMV infection. Transplant Proc 39 (2007) 993
8. Hadaya K., Wunderli W., Deffernez C., et al. Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay. J Clin Microbiol 41 (2003) 3757
9. Geddes C.C., Church C.C., Collidge T., et al. Management of cytomegalovirus infection by weekly surveillance after renal transplant: analysis of cost, rejection and renal function. Nephrol Dial Transplant 18 (2003) 1891
10. The CARI guidelines. CMV disease and kidney transplant: diagnostic tests for cytomegalovirus in renal transplantation. Nephrology (Carlton) 9 suppl 3 (2004) S23
11. Roberts T.C., Buller R.S., Gaudreault-Keener M., et al. Effects of storage temperature and time on qualitative and quantitative detection of cytomegalovirus in blood specimens by shell vial culture and PCR. J Clin Microbiol 35 (1997) 2224
12. Brennan D.C., Garlock K.A., Lippmann B.A., et al. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 8 (1997) 118
13. Patel R., and Paya C.V. Infections in solid-organ transplant recipients. Clin Microbiol Rev 10 (1997) 86
14. Pouteil-Noble C., Ecochard R., Landrivon G., et al. Cytomegalovirus infection-an etiological factor for rejection?. A prospective study in 242 renal transplant patients. Transplantation 55 (1993) 851
15. Schnitzler M.A. Costs and consequences of cytomegalovirus disease. Am J Health Syst Pharm 60 (2003) S5
16. Abbott K.C., Hypolite I.O., Viola R., et al. Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. Ann Epidemiol 12 (2002) 402
17. Hanto D.W., Jendrisak M.D., So S.K., et al. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial. Transplantation 57 (1994) 377
18. Matas A.J., Tellis V.A., Quinn T.A., et al. Timing of cyclosporine administration in patients with delayed graft function. J Surg Res 43 (1987) 489
19. Filo R.S., Smith E.J., and Leapman S.B. Reversal of acute renal allograft rejection with adjunctive AG therapy. Transplant Proc 13 (1981) 482
20. Siu C.W., Chan T.M., Li F.K., et al. Association between anti-thymocyte globulin administration and cytomegalic virus infection and/or CMV disease in cadaveric renal allograft recipients. Transplant Proc 32 (2000) 1932
21. Gurk-Turner C., Airee R., Philosophe B., et al. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Transplantation 85 (2008) 1425
22. Huurman V.A., Kalpoe J.S., van de Linde P., et al. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. Diabetes Care 29 (2006) 842